Organogenesis (ORGO) Set to Announce Quarterly Earnings on Tuesday

Organogenesis (NASDAQ:ORGO) will release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Organogenesis to post earnings of ($0.02) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. The business had revenue of $130.23 million for the quarter, compared to the consensus estimate of $122.48 million. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Stock Performance

Organogenesis stock opened at $3.28 on Friday. The company’s 50-day moving average price is $2.90 and its 200-day moving average price is $2.78. The company has a quick ratio of 2.42, a current ratio of 2.73 and a debt-to-equity ratio of 0.22. The company has a market cap of $434.83 million, a PE ratio of -25.23 and a beta of 1.60. Organogenesis has a twelve month low of $1.96 and a twelve month high of $4.70.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.